Skip to main content

Ergomed plc (2EM.DE)

Frankfurt Stock Exchange (XETRA) Healthcare BiotechnologyView data quality →
53.5Fair

ValueMarkers Composite Index

Top 48%#23,040 of 44,707

DCF data not available

Piotroski
4/9
Neutral
Beneish
-2.17
Investigate
Altman
10.49
Safe
DCF Value
-
N/A
ROIC
17.2%
Strong
P/E
44.8
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Ergomed plc (2EM.DE) — VMCI valuation read

Across 120 indicators, Ergomed plc (2EM.DE) lands at VMCI 54/100. The Healthcare sector median is 50, so the 4-point above-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 2EM.DE in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 2EM.DE trades at 25.0x earnings, 39% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 0.1x leaves covenant headroom for 2EM.DE on the trailing balance sheet.

2EM.DE fell 2.6% over the trailing 7 days, with a +1.6% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 2EM.DE’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.